Edesa Biotech, Inc. balance sheet EDSA

Annual Quarterly

As of Jun 30, 2026, Edesa Biotech, Inc. had total assets of $12.7 million. Total assets were down 14.1% from a year earlier. Stockholders' equity was $8.8 million. Cash and investments were $10.3 million. The current ratio, current assets divided by current liabilities, was 2.76.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Sep 30, 2025	FY 2024 Sep 30, 2024	FY 2023 Sep 30, 2023	FY 2022 Sep 30, 2022	FY 2021 Sep 30, 2021	FY 2020 Sep 30, 2020	FY 2019 Sep 30, 2019	FY 2018 Sep 30, 2018	FY 2017 Sep 30, 2017	FY 2016 Sep 30, 2016
Assets
Cash	10 -16.9%	11 +980.0%	1 -81.5%	5 -23.8%	7 -9.5%	8 +8.7%	7 +43.4%	5 +19.1%	4 -7.6%	5 -38.4%	7 +87.5%
Short-term investments	—	—	—	—	—	—	—	—	6 +204.8%	2 -50.0%	4 -20.5%
Cash and investments	10 -16.9%	11 +980.0%	1 -81.5%	5 -23.8%	7 -9.5%	8 +8.7%	7 +43.4%	5 -51.2%	10 +56.9%	7 -42.4%	11 +27.1%
Receivables	—	—	—	—	—	3 +3677.0%	0 -59.7%	0 +426.4%	0 +3104.8%	0 -98.5%	0 -45.5%
Inventory	—	—	—	—	—	—	—	—	0 +229.3%	0 -72.7%	0 -55.2%
Total current assets	11 -15.5%	12 +587.1%	2 -74.0%	6 -29.2%	9 -24.8%	12 +49.2%	8 +43.6%	6 -47.0%	11 +57.7%	7 -44.1%	12 +22.6%
Property and equipment, net	—	—	0 -100.0%	0 -31.4%	0 -15.3%	0 +1.2%	0 -79.7%	0 -93.1%	1 +20.8%	1 +16.3%	1 +50.2%
Total assets	13 -14.1%	14 +254.8%	4 -57.1%	9 -23.2%	12 -20.6%	15 +35.5%	11 +88.2%	6 -51.5%	12 +52.6%	8 -40.3%	13 +24.6%
Liabilities and equity
Total current liabilities	4 +481.3%	1 -41.2%	2 +0.6%	2 -14.9%	2 +46.8%	1 -4.7%	2 +231.4%	0 -6.4%	0 +53.7%	0 -48.5%	1 -73.8%
Total liabilities	—	—	2 -0.5%	2 -15.7%	2 +43.1%	2 -7.7%	2	—	—	—	—
Stockholders' equity	9 -37.7%	12 +528.5%	2 -71.9%	7 -24.9%	9 -28.1%	13 +96.9%	7 +26.2%	5 -53.4%	11 +52.5%	7 -39.9%	12 +53.8%
Debt
Lease liabilities	—	0 -100.0%	0 -79.0%	0 +398.0%	0 -80.9%	0 -39.5%	0	—	—	—	—
Total debt	—	0 -100.0%	0 -79.0%	0 +398.0%	0 -80.9%	0 -39.5%	0	—	—	—	—
Net cash	—	11 +1001.9%	1 -81.5%	5 -25.0%	7 -8.6%	8 +9.8%	7	—	—	—	—
Ratios
Current ratio	2.76x	10.67x	0.91x	3.53x	4.25x	8.29x	5.30x	12.23x	21.60x	21.06x	19.40x
Debt to equity	—	0.00x	0.01x	0.01x	0.00x	0.01x	0.02x	—	—	—	—
Return on equity	-160.05%	-57.71%	-311.44%	-118.81%	-186.86%	-102.18%	-95.96%	—	-44.65%	-67.99%	-40.82%
Return on assets	-110.85%	-53.11%	-161.77%	-94.20%	-151.60%	-91.49%	-59.13%	—	-42.78%	-65.16%	-38.85%
Book value per share	0.91	1.74	0.61	2.29	3.95	0.98	0.69	0.70	2.12	4.92	1.21

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: EDSA (Nasdaq)
Fiscal year ends: September 30
Incorporated in: British Columbia, Canada
Headquarters: Toronto
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1540159
Former names: Stellar Biotechnologies, Inc. (until May 30, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.